A. Jucov

发表

Treatment Steps, Surgery, and Hospitalization Rates During the First Year of Follow-up in Patients with Inflammatory Bowel Diseases from the 2011 ECCO-Epicom Inception Cohort.

P. Lakatos, P. Munkholm, E. Langholz, 2015, Journal of Crohn's & colitis.

Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.

M. Bazinet, A. Krawczyk, U. Dittmer, 2020, Gastroenterology.

Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection

W. Talloen, P. Tangkijvanich, E. Gane, 2022, Journal of Antimicrobial Chemotherapy.

A randomized phase 1b trial of the active site polymerase inhibitor nucleotide ATI‐2173 in patients with chronic hepatitis B virus infection

Katherine E Squires, D. Mayers, R. Melara, 2022, Journal of viral hepatitis.

Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP‐Based Therapy

M. Bazinet, G. Cloherty, U. Dittmer, 2021, Hepatology communications.

FRI-210-Establishment of high rates of functional cure of HBeAg negative chronic HBV infection with REP 2139-Mg based combination therapy: Ongoing follow-up results from the REP 401 study

M. Bazinet, A. Krawczyk, A. Vaillant, 2019, Journal of Hepatology.

Benefit of transaminase elevations in establishing functional cure of HBV infection during nap‐based combination therapy

M. Bazinet, A. Krawczyk, U. Dittmer, 2021, Journal of viral hepatitis.

Randomised clinical trial: a phase 1b study of GB004, an oral HIF‐1α stabiliser, for treatment of ulcerative colitis

R. Osterhout, J. Bruey, W. Sandborn, 2022, Alimentary pharmacology & therapeutics.

HBsAg isoform dynamics during NAP‐based therapy of HBeAg‐negative chronic HBV and HBV/HDV infection

M. Bazinet, G. Cloherty, U. Dittmer, 2022, Hepatology communications.

A combination of AT-527, a pan-genotypic guanosine nucleotide prodrug, and daclatasvir was well-tolerated and effective in HCV-infected subjects

S. Bourgeois, J. Sommadossi, N. Brown, 2020, Journal of Hepatology.

Safety, pharmacokinetics, and antiviral activity of the class II capsid assembly modulator ALG-000184 in subjects with chronic hepatitis B

M. Yuen, J. Niu, Qingling Zhang, 2022, Journal of Hepatology.

Sustained 12 week off treatment antiviral efficacy of ATI-2173, a novel active site polymerase inhibitor nucleotide, combined with tenofovir disoproxil fumarate in chronic hepatitis B patients, a phase 2a clinical trial

Katherine E Squires, D. Mayers, Myreen E. Tomas, 2022, Journal of Hepatology.

Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment naïve caucasian patients with chronic HBeAg negative HBV infection

M. Bazinet, A. Krawczyk, A. Vaillant, 2017, Journal of Hepatology.

P294 AMT-101, a gut selective oral IL-10 fusion: results from a Phase 1b study in patients with active Ulcerative Colitis

S. Schreiber, M. Garovoy, M. Posch, 2021 .

Editorial: protecting hypoxia‐inducible factor 1a and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis? Authors' reply

R. Osterhout, J. Bruey, W. Sandborn, 2022, Alimentary pharmacology & therapeutics.